

Ala Yaromina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4263220/publications.pdf>

Version: 2024-02-01

36
papers

1,261
citations

331259

21
h-index

360668

35
g-index

36
all docs

36
docs citations

36
times ranked

1945
citing authors

#	ARTICLE	IF	CITATIONS
1	Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. <i>Cancers</i> , 2021, 13, 1468.	1.7	24
2	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764.		23
3	Value of functional in-vivo endpoints in preclinical radiation research. <i>Radiotherapy and Oncology</i> , 2021, 158, 155-161.	0.3	3
4	Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2372-2383.	1.9	17
5	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 49-55.	0.9	11
6	Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape. <i>PLoS Computational Biology</i> , 2020, 16, e1008041.	1.5	13
7	A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. <i>Journal of Immunological Methods</i> , 2020, 487, 112899.	0.6	23
8	Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. <i>Molecular Oncology</i> , 2020, 14, 1555-1568.	2.1	29
9	Hypoxia PET Imaging with [18F]-HX4- A Promising Next-Generation Tracer. <i>Cancers</i> , 2020, 12, 1322.	1.7	35
10	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
11	Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. <i>Radiotherapy and Oncology</i> , 2019, 141, 247-255.	0.3	19
12	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 62-69.	0.9	86
13	An orthotopic non-small cell lung cancer model for image-guided small animal radiotherapy platforms. <i>British Journal of Radiology</i> , 2019, 92, 20180476.	1.0	17
14	HIF-1 α and HIF-2 α Differently Regulate the Radiation Sensitivity of NSCLC Cells. <i>Cells</i> , 2019, 8, 45.	1.8	48
15	Role of hypoxia-activated prodrugs in combination with radiation therapy: An <i>in silico</i> approach. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 6257-6273.	1.0	11
16	The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. <i>Oncolmmunology</i> , 2018, 7, e1414119.	2.1	36
17	Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells. <i>Oncotarget</i> , 2018, 9, 26800-26816.	0.8	25
18	Synergistic Effects of NOTCH1 β -Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells. <i>Frontiers in Oncology</i> , 2018, 8, 460.	1.3	22

#	ARTICLE	IF	CITATIONS
19	Prognostic Role of Hypoxia-Inducible Factor-2 \pm Tumor Cell Expression in Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2018, 8, 224.	1.3	43
20	Combining radiotherapy with immunotherapy: the past, the present and the future. <i>British Journal of Radiology</i> , 2017, 90, 20170157.	1.0	99
21	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume". <i>Radiotherapy and Oncology</i> , 2017, 124, 513-520.	0.3	22
22	Therapeutic options to overcome tumor hypoxia in radiation oncology. <i>Clinical and Translational Imaging</i> , 2017, 5, 455-464.	1.1	6
23	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 691-702.	2.6	22
24	Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2016, 6, 69.	1.3	129
25	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , 2016, 121, 447-452.	0.3	8
26	Synthesis and in Vivo Biological Evaluation of ⁶⁸ Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6431-6443.	2.9	33
27	The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. <i>PLoS ONE</i> , 2016, 11, e0161040.	1.1	14
28	Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. <i>Radiotherapy and Oncology</i> , 2015, 116, 438-442.	0.3	30
29	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. <i>Clinical Cancer Research</i> , 2015, 21, 2984-2992.	3.2	95
30	Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. <i>Clinical Cancer Research</i> , 2015, 21, 1151-1160.	3.2	79
31	\hat{I}^3 H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. <i>Radiotherapy and Oncology</i> , 2015, 116, 473-479.	0.3	38
32	Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake. <i>Clinical Cancer Research</i> , 2015, 21, 5511-5518.	3.2	23
33	New ways to image and target tumour hypoxia and its molecular responses. <i>Radiotherapy and Oncology</i> , 2015, 116, 352-357.	0.3	49
34	Residual \hat{I}^3 H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , 2015, 116, 480-485.	0.3	37
35	Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. <i>Radiotherapy and Oncology</i> , 2014, 111, 81-87.	0.3	34
36	Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 159-166.	0.4	29